stockportfolio.pro
KalVista Pharmaceuticals, Inc. (KALV)
Healthcare · Biotechnology · NasdaqGM
KalVista Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.13M | $1.50M | $8.39M | $16.13M | $12.69M | $0 | $0 | $0 | $50.00M | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-11.44M | $-18.60M | $-15.80M | $-20.82M | $-29.12M | $-46.24M | $-82.34M | $-92.91M | $-126.64M | $-183.44M |
| Net margin | -536.1% | -1236.9% | -188.3% | -129.1% | -229.4% | — | — | — | -253.3% | — |
Source: KalVista Pharmaceuticals, Inc. SEC filings (10-K). 14 years of history available in the interactive view.
Explore 14 years of KalVista Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track KALV in your portfolio →
KalVista Pharmaceuticals, Inc. financial history by metric
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
KalVista Pharmaceuticals, Inc. — frequently asked questions
What is KalVista Pharmaceuticals, Inc.'s revenue?
KalVista Pharmaceuticals, Inc. (KALV) reported revenue of $0 for fiscal year 2025, down 100.0% from the prior year, according to its SEC filings.
Is KalVista Pharmaceuticals, Inc. profitable?
No — KALV reported a net loss of $-183.44M in fiscal 2025.
What is KALV's P/E ratio?
KalVista Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does KalVista Pharmaceuticals, Inc. have?
As of fiscal year 2025, KALV carried roughly $139.23M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is KalVista Pharmaceuticals, Inc.'s market cap?
KalVista Pharmaceuticals, Inc. (KALV) has a market capitalization of about $1.44B, based on the latest data in our nightly-refreshed cache.
When does KalVista Pharmaceuticals, Inc.'s fiscal year end?
KALV's fiscal year ends in April. Its most recent annual filing covers the fiscal year ending 2025-04-30.
Where does this data come from?
All figures are computed from KalVista Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.